Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
02:01p Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govite..
08/16 IMMUNOMEDICS, INC. (NASDAQ : IMMU) reported earnings of ($0.48) per share missin..
08/16 IMMUNOMEDICS : reports 4Q loss
08/16 IMMUNOMEDICS, INC. (NASDAQ : IMMU) Files An 8-K Results of Operations and Financ..
08/16 Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiter..
08/07 Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fis..
08/04 IMMUNOMEDICS INC : Entry into a Material Definitive Agreement (form 8-K)
07/27 IMMUNOMEDICS : Technical Reports on Biotech Equities -- Opko Health, Array BioPh..
07/20 IMMUNOMEDICS : Researchers from Immunomedics, Inc. Detail Findings in Breast Can..
07/11 IMMUNOMEDICS : Published Results from Clinical Trials Demonstrate Therapeutic Po..
More news
News from SeekingAlpha
09:38a BIOTECH FORUM DAILY DIGEST : Agio Pharmaceuticals Back In The Spotlight
09:34a Immunomedics' IMMU-130 extends survival in mid-stage CRC study; shares up 1%
08/16 Immunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript
08/16 Immunomedics fiscal 2017 net loss $53.3M; U.S. marketing application for IMMU..
08/16 Immunomedics reports Q4 results
Financials ($)
Sales 2018 18,9 M
EBIT 2018 -94,0 M
Net income 2018 -99,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 49,6x
Capi. / Sales 2019 27,2x
Capitalization 937 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 12,5 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
Cynthia L. Sullivan Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.129.43%937
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP40.29%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.42%7 821